DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
DexCom, Inc. (DXCM) Q4 2025 Earnings Call Transcript
DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago.
DexCom heads into Q4 earnings with easing G7 issues, improving supply chains and rebounding U.S. new customer starts lifting revenue outlook.
Dexcom plans a nationwide AI upgrade to Stelo, adding a million-plus food database and smarter insights to improve glucose understanding and wellness goals.
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.